In particular, the report compares various recommended and proposed surrogates for torsades de pointes (TdP) risk. Preclinical and clinical proarrhythmia screens are discussed, including in silico methods, in vitro single cell / multicellular methods, in vivo methods and early clinical trial methods. Some discussion also is provided on mechanisms of screening for ‘direct’ (non-proarrhythmic) cardiotoxicity. In addition, the report contains the results of an industry survey undertaken by online questionnaire and by one-to-one interviews with key experts. An overview of 50 commercial entities offering cardiotoxicity screening products / services is provided. Further analysis is included regarding the competitive positioning and ownership of 29 companies that have some clear cardiotoxicity screening focus. Broad consolidation / M&A opportunities are outlined in general terms. Finally, the report provides a subjective opinion on the future of cardiotoxicity screening, suggests how regulatory guidelines might change in the future, and outlines some commercial opportunities that might be associated with the current / future cardiotoxicity screening environment.
Dr. Nicholas Miller, MD of Beremans Ltd, said “CHI / Insight Pharma were aware of work previously carried out by Beremans in the field of cardiotoxicity screening, and contacted us to discuss collaborating on an up-to-date analysis of the technical state of the art and the commercial / regulatory environment pertinent to this complex field. We were delighted to participate, as this is the type of analysis at which Beremans excels. Furthermore, it speaks to some of the core areas of focus in Beremans, including high-throughput screening.”
For further information please email:
Dr. Nicholas Miller, Managing Director, Beremans Ltd: nm01@beremans.com
